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Zebularine regulates early stages of mESC
differentiation: effect on cardiac commitment
A Horrillo1, D Pezzolla1,2, MF Fraga3, Y Aguilera1, C Salguero-Aranda2,4, JR Tejedo2,4, F Martin2,4, FJ Bedoya2,4, B Soria1,2,5
and A Hmadcha*,1,2,5
Lineage commitment during embryonic stem cell (ESC) differentiation is controlled not only by a gamut of transcription factors
but also by epigenetic events, mainly histone deacetylation and promoter DNA methylation. The DNA demethylation agent
50-aza-20-deoxycytidine (AzadC) has been widely described as an effective promoter of cardiomyogenic differentiation in various
stem cell types. However, its toxicity and instability complicate its use. Therefore, the purpose of this study was to examine the
effects of zebularine (1-(b-D-ribofuranosyl)-1,2-dihydropyrimidin-2-1), a stable and non-toxic DNA cytosine methylation inhibitor,
on mouse ESC (mESC) differentiation. Herein, we report that treating embryoid bodies, generated from mESCs, with 30 lM
zebularine for 7 days led to greater cell differentiation and induced the expression of several cardiac-specific markers that were
detected using reverse transcription-polymerase chain reaction (RT-PCR), real-time PCR, immunostaining and flow cytometry.
Zebularine enhanced the expression of cardiac markers and the appearance of beating cells that responded to cardiac drugs,
including ion channel blockers (diltiazem) and b-adrenergic stimulators (isoproterenol). Gene promoter methylation status was
assessed using methylation-specific PCR (MSP) and validated by bisulfite sequencing analysis. Global gene expression profiling
using microarrays showed that zebularine-differentiated cells are distinct from control ESCs. Pathway analysis revealed an
enhancement of cellular processes such as embryonic development, cardiovascular system development and function.
In addition, the whole-cell proteins exhibited different profiles as analyzed by two-dimensional differential-in-gel-electrophoresis.
Our results indicate that zebularine regulates mesodermal differentiation of mESCs, controls promoter methylation of crucial
cardiac genes and may help to improve cardiomyogenic differentiation.
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Embryonic stem cells (ESCs) hold a great potential for cell
replacement, despite a number of significant hurdles that still
stand in the way of the realization of that potential. The most
important among these are differentiation efficiency, safety
concerns and overcoming immune rejection.1 Currently,
ESCs and their resulting differentiated cell types provide a
promising in vitro system for the study of early human
embryonic development.2,3 As such, they can be used as cell
lines with genetic disorders4,5 and are being used increasingly
in drug screening.6,7
Differentiation of ESCs requires the repression of tran-
scription factors involved in maintaining pluripotency and the
activation of developmental genes. Both processes are
directed by specific epigenetic mechanisms. An example of
the first process is the promoter-methylation-dependent
repression of Nanog and Oct3/4 as cells differentiate.8 Thus
far, the activation of developmental genes during DNA-
demethylation-induced stem cell differentiation has been
less thoroughly studied. Instead, these developmental
genes have been reported as being in a repressed state
during the early stages of development because of the
establishment of specific patterns of histone modifications,
which consist of large regions of H3-Lys27 methylation
harbouring smaller regions of H3-Lys4 methylation.9 This
repressive chromatin state is mediated by the Polycomb
group of proteins.10–12
Besides nitric oxide (NO)13 many epigenetic compounds
efficiently invert genes’ methylation status and histone
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patterns; such compounds are currently in use for the
treatment of cancer.14 Because treatment of ESCs with
50-aza-20-deoxycytidine (AzadC) initiates cardiac differentia-
tion and gene reactivation,15,16 we tested the potential effect
of zebularine (1-(b-D-ribofuranosyl)-1,2-dihydropyrimidin-2-1)
on ESCs.
Zebularine is a cytidine analogue that is able to inhibit DNA
methyltransferases (DNMTs) through covalent binding17–19
and is a robust inhibitor of cytidine deaminase, a central
enzyme for the metabolism of cytosine nucleoside analogues
such as AzadC,20 which is increased in tumour cells as a
resistance mechanism to antineoplastic drugs. Zebularine
acts during DNA replication, substituting cytosine residues
following its phosphorylation and conversion to deoxynucleo-
tide. Once incorporated into DNA, it forms covalent com-
plexes with DNMTs leading to inhibition of its activity, thereby
decreasing DNA methylation.19 Overall, zebularine is a
genome-wide demethylating agent with increased activity in
proliferative cells.
Unlike AzadC, which is toxic in vitro and in vivo and is
unstable in aqueous solution, zebularine is chemically stable
in neutral and basic media.21,22 In addition, zebularine has a
smaller myelosuppressive effect than AzadC; this leads to
minimal side effects, making zebularine a candidate drug for
long-term tumour treatment by oral administration.22
We tested the effect of zebularine on mouse ESCs
(mESCs) and detected rhythmic and synchronized beating
areas in embryoid bodies (EBs). We next studied the gene
and protein expression of cardiac markers, finding that
zebularine-treated cells highly expressed cardiac-restricted
markers and expressed low levels of pluripotency factors.
Moreover, when gene expression was compared between
cells treated with zebularine, AzadC and NO, the cardiac
expression patterns showed that zebularine preferentially
drives the differentiation of mESCs towards a cardiomyo-
cyte-like phenotype. These findings support the hypothesis
that zebularine regulates mesodermal differentiation more
efficiently than the other drugs tested. Next, we analyzed
methylation gene promoter status and detected that Nkx2.5,
an early marker of the cardiac lineage differentiation
program, was clearly unmethylated and thus transcription-
ally activated following zebularine treatment. To decipher the
global effect of zebularine on gene expression, we per-
formed microarray analysis and found a significant number
of differentially expressed genes with a B-statistic 41,
demonstrating that the cellular transcriptome is clearly
modified following zebularine treatment. The differentially
expressed genes were selected using a linear model
approach23 and implemented in the Linear Models for
Microarray Bioconductor package and Ingenuity’s Pathway
Analysis (IPA) software. In addition, experiments having
significant signatures or reverse/antisignatures were dis-
sected using the entire mouse gene expression omnibus
(GEO) experiments on the mouse Affymetrix platform
deposited in the NCBI’s GEO database. Moreover, proteins
showed different patterns when subjected to two-dimen-
sional differential-in-gel-electrophoresis (2D-DIGE). Finally,
we studied the effect of zebularine on human ESCs (hESCs)
and observed differences in the expression levels of some
cardiac-specific genes after treatment.
Results
Zebularine preferably drives mESCs towards mesoder-
mal lineage. On the basis of the previous results demon-
strating that AzadC and NO were able to promote cardiac
differentiation of ESCs, we tested and compared the effect
of zebularine on mESCs in standard culture conditions
(þ LIF (leukemia inhibitory factor)). Using reverse tran-
scription-polymerase chain reaction (RT-PCR), we com-
pared gene expression after treatment with each of these
three molecules. When AzadC or NO was used, we
observed that pluripotency markers were expressed at
levels similar to control samples, whereas cardiac-specific
genes were slightly increased. The expression of Gata4,
Actc, Myh6, Myh7, cTnT and Anf was higher in AzadC- and
NO-treated cells than in control cells. In contrast, Serca2
was expressed similarly in all samples. The only difference
detected was the expression of cTnI in NO addition and
Hprt in AzadC treatment. Interestingly, when we compared
gene expression in zebularine-, AzadC- and NO-treated
cells, we observed that zebularine caused a reduction in
the expression of the pluripotency markers Oct3/4, Nanog
and FoxD3 than did AzadC or NO. Moreover, zebularine-
treated cells demonstrated higher expression of genes,
especially those expressed in cardiac tissues, such as
Actc, Anf, cTnT, cTnI, Myh6 and Myh7. Serca2 was
expressed at a level similar to the other samples
(Figure 1a).
As widely known, EB-mediated differentiation is the most
common method to induce spontaneous cardiac differentia-
tion; however, the results of this differentiation have been
fairly successful. Athough we postulated that zebularine
could be considered a critical parameter for optimizing early
in vitro mesodermal differentiation, we treated EBs with
30 mM of zebularine, and then we assessed the gene
expression at differentiating days 3, 5 and 7 for the three
associated lineage markers (Figure 1b). We found that
markers from different lineages are detected, interestingly,
in zebularine-treated EBs, mesoderm markers (Brachyury,
Gata4, Nkx2.5, aSMA, Desmin, Flk1, Hrt1, Mef2c BMP2,
BMP4 and Noggin), which are markedly expressed starting at
day 5; however, SM22a and Serca2 are equally detected in all
experimental conditions. Moreover both endoderm markers
(Sox17, Pdx1, FoxA2, Sox7, Pax4, P48, Mist and Nkx6.1)
and ectodermmarkers (Wt1, Snail1, Slug, Otx2, Zic1, Nestin,
Ngn, Pax6, Isl1 and Sox1) are less or not detected at
differentiating days 3, 5 and 7 when compared with control
EBs, and in addition, Oct4 and Nanog are slightly less
detected in zebularine-treated EBs compared with control
and ( LIF). These results imply that zebularine is more
efficient than AzadC or NO at promoting mesodermal gene
expression.
Because of its lower toxicity, zebularine could potentially be
used as a substitute for AzadC. To validate this hypothesis,
we measured and compared Annexin-V incorporation at
differentiating days 3, 5 and 7 (Figure 1c) and found that
apoptosis was significantly reduced in zebularine compared
with AzadC, and even more at day 3, where significant
increase of apoptosis occurs as for AzadC, thus confirming
that zebularine has no cytotoxic effect on EBs.
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Zebularine promotes the expression of cardiac-specific
genes and proteins. We used real-time PCR to analyze the
mRNA levels of genes related to cardiac differentiation, and
genes involved in the functional machinery of cardiac cells in
EBs leaved to spontaneous differentiation during 7 days
(from now on defined as Control) and EBs treated with
zebularine (from now on defined as Zebularine) (Figure 2a).
We detected elevated mRNA levels of cardiac-precursor
genes Nkx2.5 (enhanced 1.8-fold (P40.05)) and Gata4
(enhanced 2.6-fold (P40.05)), both essential for cardiac cell
commitment, elevated the expression of genes whose
encoded proteins are essential components of contractile
cardiac machinery, such as Actc, cTnI, cTnT, Myh7, Myl7
and Myl2, and increased the expression of other genes
essential for cardiac development and function, such as Anf,
Flk1, Hrt1 and Mef2c (Figure 2b).
Using western blotting (Figure 2c), we found that zebularine
promotes the expression of proteins that are restricted to
mesoderm and cardiac phenotypes, such as Gata4, Actc,
Myh7, cTnt, Anf, Desmin, Flk1 and a-actin. Immunostaining
analysis (Figure 2d) showed that the precursor Gata4 was
expressed at higher levels in zebularine-treated EBs and had
Figure 1 Effect of zebularine on mESC differentiation. (a) Detection and comparison of cardiac markers by RT-PCR in Control, AzadC, NO and zebularine treatment,
undifferentiation markers are less detected and cardiac markers showed an enhanced expression after treatments. (b) Time course of zebularine treatment on lineage
formation: mESCs cells were cultured as hanging drop during 3 days to form EBs and differentiate to derivatives of the three germ layers and then leaved in culture without
treatment (Control) or treated with 30 mM zebularine. Gene expression was assessed in parallel at differentiating days 3, 5 and 7. Cells cultured without LIF ( LIF) are used
as negative control for lineage formation. RT-PCR was performed with primers to detect pluripotency markers (Oct3/4 and Nanog), endoderm-specific markers (Sox17, Pdx1,
FoxA2, Pax4, P48, Mist and Nkx6.1), mesoderm-specific markers (Brachyury, Gata4, Nkx2.5, aSMA, SM22a, Desmin, Flk1, Hrt1, Mef2c, tbx5, BMP2, BMP4, Serca2 and
Noggin) and ectoderm-specific markers (Wt1, Snail1, Slug, Otx2, Zic1, Nestin, Ngn, Pax6. Islet1 and Sox1). b-Actin was used as the input control. (c) Apoptosis comparison
for control-, zebularine- and AzadC-treated EBs. Time-course analysis and comparison of Annexin-V binding at differentiating days 3, 5 and 7, indicating that cells treated with
zebularine are not undergoing apoptosis. Values were normalized from the means of the controls. Data are representative of three independent experiments statistically
analyzed with analysis of variance (ANOVA) I (*Po0.05, **Po0.01 and ***Po0.001). Different letters at the top of the bars represent statistically different values; same
letters represent statistically same values in discriminatory analysis Tukey’s B test
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a primarily nuclear distribution, whereas no expression was
detected in control cells. Moreover, Actc and Myh7 proteins
were markedly increased in cells treated with zebularine. Actc
was clearly distributed in the cellular cytoskeleton and cellular
prolongations in comparison to control cells, which only
expressed low levels of this protein. Myh7 demonstrated a
similar cytoskeletal distribution in treated cells and was not
detected in control. Anf was expressed after zebularine
treatment but not in control cells. Furthermore, Flk1 and
Desmin, two proteins involved in cardiovascular system
development, had increased expression following zebularine
treatment (Figure 2d). Finally, by flow cytometry analysis we
detected that cells treated with zebularine were more positive
to proteins involved in cardiac differentiation and functionality
(Figure 2e). Zebularine-treated cells are 15.17% more
positive to Gata4, 10.53% to Actc, 4.29% to Flk1, 7.99% to
Myh7, 5.18% to sarcomeric-Actc, 8.83% to Anf and 4.09% to
Desmin. These results suggest that zebularine is able to
induce the expression of cardiac-specific genes and proteins.
The beating areas resulting from zebularine treatment
respond to chronotropic drugs. Zebularine treatment
resulted in the appearance of beating areas that showed
rhythmic and coordinated contractions (Supplementary
Movie 1). To determine whether these contractions were
functional, we used cardiotropic drugs to alter beating
frequency. We administrated isoproterenol, which acts on
b-adrenergic receptors, and diltiazem, a calcium channel
blocker that produces a decrease in cardiac rhythm,
provoking negative ionotropic and chronotropic function.
After the addition of 2 mM isoproterenol (Figure 3a), we
observed a 135.00% enhancement in contraction frequency
after 1min and a 126.25% enhancement after 2min of
exposure, demonstrating that isoproterenol provokes a very
Figure 2 Zebularine promotes an overexpression of cardiac markers. (a) Timeline approach for differentiation of mESCs, showing the time periods for EBs formation, EBs
adhesion, untreated control cells (no addition) and zebularine application. (b) Real-time PCR showing an overexpression of genes essential for cardiac development and
function after zebularine treatment. The histograms represented the fold increase of each gene after treatment compared with the basal level of untreated control cells. Results
are means±S.D. for three different experiments. (c) Western blot detection of cardiac protein expression; b-actin was used as a loading control. (d) Immunodetection
corroborated the cardiac lineage markers after zebularine treatment; nuclei were stained with 40,6-diamidino-2-phenylindole (DAPI) (blue). Scale bars; 50 mm. (e) Results from
flow cytometric analysis showing the percentage of cells expressing cardiac-specific proteins in control and zebularine conditions. Data are represented as mean±standard
error (±S.E.) for three different experiments. Statistical significance (*Po0.05) was determined by t-test
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fast response in treated cells and that these cells possibly
possess functional b-adrenergic receptors. On the other
hand, and as we expected, 50 mM diltiazem (Figure 3b) led to
complete inhibition of contraction 71.6 s after its addition
(Supplementary Movies 1–3). Hence, zebularine promotes
the differentiation of mESCs towards contractile cells that
respond to cardiotropic regulators.
Zebularine modifies the promoter methylation state of
Nkx2.5. To determine whether zebularine produces changes
in the methylation patterns, we studied gene promoter
methylation status using methylation-specific PCR (MSP).
As Figure 4a depicts, the pluripotency markers Oct3/4 and
Nanog were transcriptionally active in control samples
(unmethylated). This contrasts with zebularine-treated EBs,
which had methylated promoters, suggesting that zebularine
induced methylation-based gene silencing. In contrast, the
Sox2 promoter was unmethylated in both samples, indicating
that Sox2 expression was unaffected by zebularine. Moreover,
the promoters of Gata4 and Serca2 were in an unmethylated
state in both control and treated cells, suggesting that the
expression of these genes was unaffected by zebularine.
Interestingly, Nkx2.5 was epigenetically repressed in
control cells, but appeared unmethylated in zebularine-
treated cells. As Nkx2.5 associates with members of the
GATA family, activates cardiac structural genes and is
essential to initiate the cardiac differentiation, these data
indicate that zebularine was able to induce demethylation of
Nkx2.5, which leads to its expression, thereby promoting the
expression of other fundamental genes during the cardiac
differentiation of ESCs.
To confirm and validate the promoter methylation status of
Nkx2.5 and Gata4, bisulfite-treated genomic DNAs obtained
from Control, zebularine and AzadC samples were amplified,
Figure 3 Effects of chronotropic drugs in zebularine-treated cells. (a) Median of beating frequency in samples 1 and 2min after treatment with 2 mM isoproterenol. Results
are means±S.D. for 50 different areas from three experiments. ***A statistically significant difference of isoproterenol administration compared with zebularine (paired
Student’s t-test; Po0.001). (b) Contraction frequency registration of nine contractile areas from three different experiments showing that 2 mM isoproterenol increased beating
frequency and 50mM diltiazem was able to stop contractions 71.6 s after administration
Figure 4 Analysis of gene promoter’s methylation under zebularine treatment. (a) MSP of pluripotency and cardiac lineage markers showing that the promoters of both
Oct3/4 and Nanog shifted from unmethylated (U) to methylated (M) state; the promoter of Nkx2.5 becomes unmethylated after zebularine treatment and no promoter
methylation was detected in any of the other cardiac markers analyzed. (b) Bisulfite sequencing from five clones of Gata4 CpG island for Control, zebularine and AzadC-
treated EBs, indicating that the promoter remains unmethylated in 15 CpG sites. (c) Bisulfite sequencing from five clones of Nkx2.5 promoter revealed that zebularine
unmethylated almost all of the 43 CpG sites analyzed. The percentage of methylation is presented as the percentage of filled circles over total circles for a given CpG site from
each clone analyzed: ¼ 0%; ¼ 40%; ¼ 60%; ¼ 80%; ¼ 100%
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cloned and sequenced. As shown in Figure 4b, we found that
the methylation pattern did not change and the Gata4
promoter remains completely unmethylated, however; and
in concordance with the MSP results, Nkx2.5 promoter was
almost completely unmethylated for zebularine and predomi-
nately methylated for AzadC (Figure 4c).
Consequently, we analyzed the activity of DNA demethy-
lases and DNMTs. Following zebularine addition, DNA
demethylase activity was significantly enhanced by 129.01%
(Po0.01), whereas DNMT activity was reduced 14.20%
(P¼ 0.01) compared with control cells (Figure 5a). These
data suggest that promoter methylation is reduced when cells
are treated with zebularine and subsequently zebularine acts
on DNMTs, decreasing their activity.
We also studied histone methyltransferase (HMT) activity
for histone H3 lysine 9 (H3K9) and histone H3 lysine 4 (H3K4).
After zebularine treatment, we found a 60.77% (P¼ 0.017)
reduction of HMT activity at H3K9, which is considered a
marker for heterochromatin. In addition, the HMT activity at
H3K4, a hallmark of euchromatin, was increased by 32.8%
(P¼ 0.01) after zebularine treatment (Figure 5b). We also
detected that histone deacetylase (HDAC) activity was
reduced by 52.74% (P¼ 0.017) compared with control
samples, indicating that chromatin exists in a more relaxed
Figure 5 Zebularine treatment caused (a) an increment of global demethylase activity and a decrease of DNTMs activity (b) a decrease of HMT (H3K9) and increase of
H3K4 (c) reduction of global HDAC activity. Blots are representative of 4 independent experiments. (d) Western blot detection after zebularine treatment of acetylated state of
histone H4, and methylated state of histones H3K4me3 and H3K9me1, b-actin was used as loading control
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conformation in treated samples (Figure 5c). Although
zebularine enhanced histone H4 acetylation, the acetylation
state of histones plays a central role in determining gene
expression and its overexpression could indicate a transcrip-
tional upregulation; H3K4 and H3K9 methylation are detect-
able in zebularine-treated cells, the level of H3K9 methylation
appears no different compared with control and H3K4
methylation appears slightly increased (Figure 5d), indicating
the establishment of a specific pattern of histone modification.
These data indicate that zebularine acts as a chromatin-
modifying agent, inducing methylation and silencing of Oct3/4
and Nanog, both of which are essential to maintain pluripo-
tency. In addition, this drug is able to demethylate and
increase the expression of Nkx2.5, which directs cells to enter
a cardiomyocyte differentiation program. Moreover, zebular-
ine indirectly alters the activity of enzymes that are implicated
in the epigenetic regulation of gene transcription and
chromatin structure.
Zebularine alters global gene expression profiling. To
characterize the genome-wide gene expression profile, we
used Affymetrix microarray platform. A set of differentially
expressed genes is presented as a heatmap to illustrate
groups of coregulated genes; hierarchical clustering
(Figure 6a) indicated that the gene expression profile of
zebularine is distinct from that of control. The data were then
globally normalized, filtered and deposited in NCBI’s GEO
database (GSE29072). Using Gene Ontology categories,
266 genes (119 upregulated and 147 downregulated) were
identified from a total of 45 102 genes as having an
expression level that differed significantly (Po0.001) upon
zebularine treatment. The potential functions and known
biological roles of these genes are listed in Supplementary
Table 2. Data were most associated with biological process,
system development, organ and multiorgan development,
anatomical structure development, anatomical structure
morphogenesis, cellular components and molecular func-
tions. Some of the genes upregulated by zebularine matched
the mesoderm markers, these include BMP4 and Brachyury.
We compared our microarray results with the results from
other studies by analyzing all mouse GEO studies that used
the mouse Affymetrix platform in the GEO database. A high
positive score implies that the mouse GEO studies shares
over- and underexpressed signatures with our experiment,
whereas a high negative score indicates a reverse or
antipattern compared with our study. The scores were
Figure 6 Microarrays, IPA analysis and proteomics assays for zebularine-treated cells. (a) Hierarchical clustering of the gene expression changes between zebularine and
Control. The columns represent different replica of each condition replica. A red color represents upregulation, whereas a blue color represents downregulation. (b) Plot for
biological functions generated by IPA analysis showing enhanced threshold for those related to cardiomuscular development. Enrichment score (y axis) is reported as the
minus log transformation on the geometric mean of P-values from the enriched annotation terms associating with one or more of the gene group members. The genes are
clustered into significantly enriched groups for specific biological functions. (c) Comparison of control- and zebularine-treated cells proteins using 2D-DIGE. Protein fractions
from control were labeled with Cy3 (green) and zebularine ones with Cy5 (red), and then mixed. The mixed protein samples were separated by isoelectric focusing, and then
SDS-PAGE. Merge picture from the superposition of fluorescence images shows a pool of proteins with differential mobility in zebularine condition (arrows)
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DNA demethylation effect on dermal fibroblasts: Aza-dCo¼4untreated (agent) (GSE4696) 1.04 o0.0001
Transcription factors Nanog and Oct4 knockdown effect on ESCs: Nanog knockdowno¼4Control
(protocol) (GSE4189)
1 o0.0001
ESC line response to the conditional expression of neurogenin 3: 3 dayso¼40 days (time) (GSE3653) 0.95 o0.0001
NA demethylation effect on terminally differentiated cells: 5-aza-2dCo¼4control (agent) (GSE4768) 0.885 o0.0001
Cell culture model of extraembryonic endoderm: R1o¼4IM8A1-I (ratio) (cell line) 0.883 o0.0001
Hair follicle and skin molecular signatures: matrixo¼4dermal papilla (cell type) 0.846 o0.0001
Transcription factor Nrl deficiency effect on photoreceptor development: P2o¼4E16 (development stage) 0.839 o0.0001
Glucosamine and high glucose effect on renal mesangial cells: 25mM glucoseo¼4control (agent) 0.837 o0.0001
Phosgene effect on lungs: time course 12 ho¼40 h (time) 0.835 o0.0001
Blastocyst response to variousMAPKpathway inhibitors (MOE430A): JNK inhibitoro¼4untreated (ratio) (agent) 0.827 o0.0001
DNA demethylation effect on terminally differentiated cells: osteoblasto¼4fibroblast (cell type) 0.822 o0.0001
Blastocyst response to various MAPK pathway inhibitors (MOE430 2.0): JNK inhibitoro¼4untreated (agent) 0.818 o0.0001
Trans-10, cis-12-conjugated linoleic acid delipidiative effect on white adipose tissues: time course trans-10, cis-
12-conjugated linoleic acido¼4control (agent)
0.807 o0.0001
Estrogen effect on lung: time course 6 ho¼43 h (time) 0.801 o0.0001
Mechanical stress effect on fibroblasts from various fetal tissues (MG-430A): tendon fibroblasto¼4skin
fibroblast (cell line)
0.797 o0.0001
Spinal cord injury model: time course site of traumao¼4caudal to trauma (specimen) 0.794 o0.0001
DNA demethylation effect on terminally differentiated cells: osteoblasto¼4chondrocyte (cell type) 0.791 o0.0001
Transcription factor Oct1-deficient fibroblast response to ionizing radiation (430A): g-radiationo¼4control
(agent)
0.79 o0.0001
Pancreatic development (MG-U74B): E14.5o¼4E12.5 (age) 0.79 o0.0001
Topoisomerase IIb deficiency effect on the developing embryonic brain: topIIb nullo¼4wild type (genotype/
variation)
0.79 o0.0001
Phosgene effect on lungs: time course 24 ho¼40 h (time) 0.788 o0.0001
Oocyte development (MOE430B): secondary follicleo¼4primary follicle (development stage) 0.785 o0.0001
Oocyte development (MOE430B): 12 dayso¼46 days (age) 0.785 o0.0001
CH1 domain deletion, p300 and CBP heterozygous-null mutant fibroblasts response to hypoxia:
normoxiao¼4hypoxia (stress)
0.78 o0.0001
Hair follicle and skin molecular signatures: matrixo¼4dermal fibroblasts (cell type) 0.772 0.006818
Conjugated linoleic acid delipidative effect on obese line: time course (dye-swap) 14 days (ratio) (time) 0.771 0.006818
Cardiac development in embryo: E14.5o¼4E11.5 (development stage) (GSE1479) 0.771 0.006818
Pancreatic development (MG-U74B): E15.5o¼4E12.5 (age) 0.763 0.006818
Differential repression of TLR responses by PPARg and LXRs: GW7845o¼4none (treatment) 0.76 0.006818
Corneal stromal cell differentiation: adulto¼410 days postnatal (protocol) 0.758 0.006818
Fibroblast growth factor 2 effect on embryonic fibroblast: dose response 40ng/mlo¼44ng/ml (ratio) (dose) 0.75 0.01271
Epididymis development: postnatal day 0.5o¼4gestational day 18 (age) 0.75 0.01815
Pancreatic development (MG-U74B): E13.5o¼4E12.5 (age) 0.748 0.01815
ERK MAP kinase inactivation during G0/G1-to-S-phase transition: time course FGFo¼4control (protocol) 0.748 0.01852
Testis developmental time course: embryonic (MG-U74A): 18.5 d.p.c.o¼411.5 d.pc. (development stage) 0.746 0.01852
Phosgene effect on lungs: time course 8 ho¼40 h (time) 0.741 0.01852
Testis development: gestation day 16o¼4gestation day 12 (time) 0.741 0.01852
Cardiac development in embryo: E16.5o¼4E11.5 (development stage) (GSE1479) 0.74 0.01852
Ovary development: gestational day 14o¼4gestational day 12 (age) 0.738 0.01852
Phosgene effect on lungs: time course 48 ho¼40 h (time) 0.736 0.01852
Acute myocardial infarction model: time course (MG-U74B) 48ho¼44 h (time) 0.736 0.01852
Heart failure and NO eNOS knockouto¼4wild type (strain) 0.736 0.01852
Embryonic kidney: ureteric bud and metanephric mesenchyme (MOE430 2.0): ureteric bud tipo¼4ureteric bud
stalk (tissue)
0.734 0.01852
MAP kinase activation effect on heart: time course MKK3bE transgenico¼4control (genotype/variation) 0.729 0.01852
Glycerol kinase knockout effect on liver glycerol kinase knockouto¼4wild type (genotype/variation) 0.729 0.01852
Myotube response to PGC-1a-induced mitochondrial biogenesis: time course (MG-U74B) 3 dayso¼40 days
(time)
0.728 0.02131
Cardiac development in embryo: E18.5o¼4E11.5 (development stage) (GSE1479) 0.725 0.02131
Pancreatic development (MG-U74B): E16.5o¼4E12.5 (age) 0.725 0.02131
Lymphotoxin-b receptor signaling inhibition effect on lymph nodes: time course (MG-430B) 35 dayso¼427 days
(time)
0.72 0.02394
Spermatogonial stem cell activity in testis laminin binding germ cells (MG-U74C): laminin bindingo¼4interstitial
(cell type)
0.72 0.02394
Phosgene effect on lungs: time course 72 ho¼40 h (time) 0.72 0.02394
Pyruvate effect on muscle cells: sodium pyruvateo¼4untreated (agent) 0.72 0.02394
Hematopoietic cells at various stages of differentiation: granulocyteo¼4ST-HSC (ratio) (development stage) 0.719 0.02394
Hippocampus of various inbred strains: DBA/2Jo¼4129S1/SvImJ (strain) 0.717 0.02706
Phosgene effect on lungs: time course 8 ho¼44 h (time) 0.716 0.02706
Gonadal somatic cells during the critical period of sex determination: time course 11.5 d.p.c.o¼410.5 d.p.c.
(age)
0.714 0.0303
Embryonal carcinoma cell line response to retinoic acid or trichostatin A: trichostatin Ao¼4control (agent) 0.711 0.03571
Uniparental duplication of chromosome 7 regions effect on various tissues (MG-U74A): 13.5 d.p.c.
placentao¼413.5 d.p.c. embryo (tissue)
0.709 0.03892
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MAP kinase activation effect on heart: time course maleo¼4female (gender) 0.708 0.04206
Acute myocardial infarction model: time course (MG-U74A) 24ho¼412h (time) 0.706 0.04239
Transcription factor Oct1 deficient fibroblast response to ionizing radiation (430B): g-radiationo¼4control
(agent)
0.705 0.04239
Phosgene effect on lungs: time course phosgeneo¼4none (agent) 0.705 0.04239
Osteoblast differentiation (MG-U74B): 17 dayso¼47 days (time) 0.704 0.04239
Ovary development: gestational day 14o¼4gestational day 11 (age) 0.702 0.04239
Hyperoxic lung injury (U74Cv2): Nrf2 mutanto¼4wild type (strain) 0.701 0.04487
Testis development: gestation day 14o¼4gestation day 12 (time) 0.7 0.04487
Embryonic kidney: ureteric bud and metanephric mesenchyme (MOE430 2.0): ureteric bud tipo¼4metanephric
mesenchyme (tissue)
0.699 0.04611
Oocyte development (MOE430B): 22 dayso¼46 days (age) 0.696 0.04611
Cystic fibrosis transmembrane conductance regulator deficiency in different genetic backgrounds: CFTR
deficiento¼4control (genotype/variation)
0.695 0.04611





Oocyte development (MOE430B): primary follicleo¼4large antral follicle (development.stage) 0.695 0.04611
Male and female salivary gland comparison: submandibular glando¼4meibomian gland (tissue) 0.698 0.04611
Corneal stromal cell differentiation: keratocyteo¼4cornea (cell type) 0.702 0.04239
Male and female salivary gland comparison: submandibular glando¼4parotid gland (tissue) 0.706 0.04239
Uniparental duplication of chromosome 7 regions effect on various tissues (MG-U74A): newborn
hearto¼413.5 d.p.c. placenta (tissue)
0.707 0.04239
PGC-1a-null brown adipocyte response to cAMP: PGC-1a nullo¼4wild type (genotype/variation) 0.711 0.03571
Hair follicle development: time course 1 dayo¼41 year (age) 0.711 0.03571
Smooth muscle cell differentiation induced by retinoic acid: time course control (agent) (GSE1506) 0.712 0.03309
Smooth muscle cell differentiation induced by retinoic acid: time course 0h (time) (GSE1506) 0.712 0.03309
Testis development: postnatal day 2o¼4gestation day 14 (time) 0.713 0.03309
Extraocular and hindlimb skeletal muscle cell differentiation: time course (MG-430B): 24 ho¼40 h (time) 0.714 0.0303
Ovary development: gestational day 18o¼4gestational day 14 (age) 0.716 0.02706
Male and female salivary gland comparison:submandibular glando¼4lacrimal gland (tissue) 0.718 0.02394
Guided differentiation into dopaminergic neurons and random differentiation into EBs neural precursors (stage 3)
(development stage)
0.721 0.02131
Myogenic transcription factor MyoD mutant expression effect on embryonic fibroblast: time course 24ho¼46 h
(time)
0.721 0.02131
Spermatogonial stem cell self-renewal: time course 18ho¼4control (time) 0.722 0.02131
Spermatogonial stem cell self-renewal: time course GDNF, GFRa1 withdrawalo¼4GDNF, GFRa1 pre-
withdrawal (protocol)
0.722 0.02131
Male and female salivary gland comparison: sublingual glando¼4parotid gland (tissue) 0.729 0.01852
Embryonic stem cell line response to the conditional expression of neurogenin 3 undifferentiated:
ESCso¼4EBs (development stage) (GSE3653)
0.73 0.01852
Pubertal mammary gland development: 4 weekso¼4 3 weeks (age) 0.734 0.01852
Medullary thymic epithelial cells medullary TECo¼4dendritic (cell type) 0.738 0.01852
Chondrocyte differentiation: time course 9 dayso¼43 days (time) 0.741 0.01852
Hematopoietic stem cell proliferation after 5-fluorouracil treatment: time course 30 dayso¼40 days (time) 0.744 0.01852
Spermatogonial stem cell self-renewal: time course 4 ho¼4control (time) 0.747 0.01852
Corneal stromal cell differentiation cell cultureo¼4adult (protocol) 0.75 0.01815
Brown fat cell response to PGC-1a and PGC-1b deficiency: PGC-1b siRNAo¼4control siRNA (agent) 0.751 0.01271
Embryonic stem cell differentiation induced by various chemicals: time course HMBA (agent) 0.754 0.01271
Hair follicle and skin molecular signatures: melanocyteso¼4matrix (cell type) 0.755 0.01271
Transcription factor Egr3 expression effect on primary myotubes (MG-430A): truncated Egr3o¼4wild-type Egr3
(genotype/variation)
0.761 0.006818
Testosterone effect on female lacrimal, meibomian and submandibular glands: submandibular glando¼4
meibomian gland (tissue)
0.765 0.006818
Hair follicle and skin molecular signatures: outer root sheatho¼4matrix (cell.type) 0.766 0.006818
Chondrocyte differentiation: time course 9 dayso¼46 days (time) 0.767 0.006818
Guided differentiation into dopaminergic neurons and random differentiation into EB-guided differentiation (growth
protocol)
0.77 0.006818
Testis development: postnatal day 2o¼4gestation day 16 (time) 0.77 0.006818
Cardiac development in embryo: whole hearto¼4both ventricles (tissue) 0.773 0.006818
ESC differentiation induced by various chemicals: time course RA (agent) (Platform GPL1261) 0.774 0.006818
Corneal stromal cell differentiation: myofibroblasto¼4cornea (cell type) 0.778 0.006818
Embryonic stem cell line response to the conditional expression of neurogenin 3: 10 dayso¼40 days
(time) (GSE3653)
0.779 0.006818
Peripheral myelin protein 22 gene dosage and point mutation effect on sciatic nerve: PMP22 knockouto¼4wild
type (genotype/variation)
0.78 0.006818
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calculated using weighted Kolmogorov–Smirnov statistics,
which were then used to generate a Connectivity Map.24
These computations were carried out using the GEO query
package of R Bioconductor and the statistical packages in R.
Out of the microarrays we analyzed, 3750 showed a
significantly similar or significantly reverse signature to our
experiment; as a first approximation, we focused on similarity/
dissimilarity scores with a Po0.05 and found 71 studies with
high similarity to our results (P-values from 0.695 to 1) and 54
studies with low similarity (P-values from  0.695 to  1)
(Table 1).
As this classification is very approximate and gives only
basic information, we also analyzed the data using IPA to
classify specific groups of genes involved in cellular functions
related to cardiogenesis (Figure 6b). Interestingly, the most
often recorded biological functions were related to skeletal,
muscular and cardiovascular system development and func-
tion, tissue development, cell-to-cell signaling and embryonic
development. In addition to these gene expression changes,
2D-DIGE proteomics assay results showed that zebularine
also affects protein mobility patterns, altering the acidic shift in
several proteins (Figure 6c).
Zebularine enhances the expression of cardiac lineage
markers in hESCs. We speculated whether zebularine was
able to produce the same effect on hESCs. To address this
issue, we used HS-181 – an hESC cell line. After 7 days of
treatment, no beating areas were detected. To determine
whether zebularine-treated hESCs possessed cardiac
expression markers, we analyzed the gene expression using
RT-PCR (Figure 7a). As with mESCs, we detected Gata4
expression in control and treated samples, and increased
expression of Actc, Myh7, Myh6, cTnI, Serca2 and Anf in
zebularine-differentiated cells; however, no expression of
Myl2 and Myl7 was detected, possibly explaining the
absence of contractile areas in treated cells. We then studied
the protein expression using immunostaining (Figure 7b) and
detected that zebularine slightly enhanced the protein levels
of Gata4, Myh7, Actc and Anf. In addition, results from an
hESC-specific protein array demonstrated a slight inhibition
of pluripotency marker expression and increased levels of
mesodermic proteins after zebularine treatment (Figures 7c
and d). As a result, zebularine is able to induce cardiac-
specific gene and protein expression in HS-181, although
less effectively than in mESCs. Future comparative investi-
gations will shed light on whether zebularine is able to induce
complete cardiac differentiation in various cell types.
Discussion
It has been widely demonstrated that ESCs are able to give
rise to cardiomyocytes when treated with growth factors and
chemical compounds.25–28 Among the many different proto-
cols used to differentiate ESCs towards cardiomyocytes,
NO addition to ESC culture was able to upregulate cardio-
myogenesis processes and inhibit cell death.29–31 AzadC has
also been demonstrated to be an activator of the cardiac
differentiation,15 although 1mM of AzadC leads to cell death
and disappearance of the cardiac phenotype. Thus, AzadC
possesses a significant limitation in producing cardiac-like
cells from ESCs because of its cytotoxicity and inability to
maintain a cardiac phenotype.
In this study, we demonstrated that zebularine is able to
induce a mesodermal differentiation in mESCs and found that
its application led to the increased expression of cardiac-
restricted genes. Beyond the overexpression of cardiomyo-
cyte-specific markers, we found that the pluripotency markers
were downregulated. Interestingly, based on gene expres-
sion, zebularine appears to be more efficient at promoting the
development of cardiac phenotypes than AzadC and NO,
particularly in light of some reports suggesting that AzadC fails
to differentiate stem cells to a cardiac lineage.32,33
Furthermore, protein expression analysis confirmed that
proteins involved in cardiac differentiation and functionality
were highly expressed in the treated cells. These data were
supported by immunostaining and flow cytometry analysis. To
Endothelial progenitor cells in fetal liver: feeder cell layero¼4LEPs_Sca1 minus (cell type) 0.789 o0.0001
ESC line response to the conditional expression of neurogenin 3: 10 dayso¼43 days (time) 0.791 o0.0001
Hematopoietic stem cell proliferation after 5-fluorouracil treatment: time course 6 dayso¼40 days (time) 0.794 o0.0001
ESC differentiation induced by various chemicals: time course 6 days (time) 0.798 o0.0001
Cell culture model of extraembryonic endoderm: ICRo¼4129/Sv (ratio) (strain) 0.807 o0.0001
Cell culture model of extraembryonic endoderm: XEN1–3o¼4R1 (ratio) (cell line) 0.807 o0.0001
Cell culture model of extraembryonic endoderm: POo¼4129/Sv (strain) 0.81 o0.0001
Antenatal steroid effect on the placenta: dexamethasoneo¼4control (agent) 0.823 o0.0001
Protein tyrosine kinase Src R388A mutant rescue by imidazole in living cells: time course Src R388A
Y527Fo¼4Src D386N Y527F (cell line)
0.836 o0.0001
Acute myocardial infarction model: time course (MG-U74B) 4 ho¼424h (time) 0.855 o0.0001
ESC differentiation induced by various chemicals: time course 2 days (time) (Platform GPL1261) 0.932 o0.0001
Embryonic stem cell differentiation induced by various chemicals: time course 4 days (time) (Platform
GPL1261)
0.963 o0.0001
ESC differentiation induced by various chemicals: time course DMSO (agent) (Platform GPL1261) 1.1 o0.0001
Bold text denotes studies that involve the use of different agents (AzadC, Retinoic Acid, DMSO) for ESC differentiation, cardiac development and DNA demethylation,
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our knowledge, this is the first time that zebularine has been
shown to differentiate ESCs towards cardiac-like cells more
efficiently than other tested drugs.
Also, we observed that zebularine addition induced
rhythmic and coordinated contractions and the ability to
respond to cardiotropic drugs, suggesting that zebularine-
treated cells possess cardiac-like functionality.
During cell differentiation, it has been suggested that the
accumulation of cell lineage-specific methylation patterns
could give rise to tissue-dependent and differentially methy-
lated regions, such as those found in some CpG islands.34
This indicates that promoter methylation of specific genes
involved in cellular differentiation may occur and thereby
commit cells towards a specific lineage. Analysis of promoter
methylation status of some genes involved in pluripotency and
cellular differentiation showed that after zebularine adminis-
tration, Oct3/4 and Nanog were transcriptionally inactivated
via DNA methylation, suggesting that these cells would be
biased towards differentiation. Meanwhile, the Nkx2.5 gene
was clearly more activated after zebularine treatment, as its
promoter became unmethylated. This indicates that cells
treated with zebularine not only decrease the expression of
pluripotencymarkers but also start to express genes that have
pivotal roles in cardiac differentiation. In addition, we have
demonstrated that zebularine is able to enhance histone H4
acetylation and modify the activity of HDAC and DNMT, in
addition to reducing the methylation of H3K9. Zebularine also
enhanced DNA demethylase activity and increased the
methylation of H3K4. Hence, these global modifications
induced by zebularine open and relax the structure of
chromatin, increasing the accessibility of promoters to
transcriptional machinery.
It has been recently suggested that DNMTs, in addition to
incorporating methyl groups into gene promoter regions, may
also enforce gene silencing through the recruitment of
transcriptional repressor protein complexes that carry pro-
teins with HDAC activity.35 This would create a scenario
where DNA methylation is correlated with the compaction of
chromatin structure. This suggestion is in concordance with
our data that demonstrate a decrease of DNMT activity in
conjunction with a decrease in HDAC activity.
Furthermore, using genome-wide expression array and
2D-DIGE protein analyses, we have demonstrated that
zebularine strongly modifies gene and protein expression.
Interestingly, our microarray data matched existing GEO
studies (with a high similarity score). However, further
analyses should be performed, at least at the protein level.
Finally, zebularine treatment of hESCs enhanced cardiac-
restricted genes and protein expression, although no beating
cells were detected. The absence of beating areas could be
explained by the fact that zebularine is incorporated into DNA
during the S phase of the cell cycle. As the doubling time of
Figure 7 Characterization of HS-181 cell line after treatment with zebularine. (a) RT-PCR of cardiac markers after treatment with zebularine. Myh7, Myh6, Actc, cTnI and
Serca2 present more expression after treatment. (b) Immunostaining of treated cells to detect cardiac-specific proteins. Scale bars; 50mm. (c) Blots of Proteome Profiler Array
and the resulting quantification histograms demonstrating inhibition of pluripotency marker expression and (d) increased levels of mesodermic proteins after zebularine
treatment (black arrows)
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hESCs is longer than that of mESCs, this would explain why
zebularine was less efficient in hESCs than in mESCs.
Moreover, a protein array panel demonstrated a quantitative
increase in mesoderm markers and a slight decrease in
pluripotency markers.
These results provide newmechanistic insights regarding the
function of zebularine during early ESC differentiation. The link
between zebularine and its epigenetic effects opens a new field
of investigation aimed at defining the rules of differentiation
processes. Indeed, the possibility of priming normal cells with
zebularine ex vivo may represent a strategy to obtain
specialized cell populations potentially useful for cell therapy.
Materials and Methods
Cell culture and drug administration. The mouse ESC cell line (ES-D3
(D3); ATCC Number: CRL-1934) was cultured in DMEM (Dulbecco’s medium) with
15% FBS, 10 U/ml penicillin, 10mg/ml streptomycin, 2 mM glutamine, 10 4 M b-
mercaptoethanol, 1 non-essential amino acids and 103 U/ml LIF, and then
maintained at 37 1C and 5% CO2. The drug administration to mESCs was
prepared in three different experimental ways: (1) standard culture conditions in
presence of LIF to compare the effect of different agents: the cells were divided
into control group, NO-treated group, Azad-C-treated group and zebularine-treated
group, control cultures (þ LIF) were left untreated and experimental cultures were
treated with 1mg/ml AzadC, 100mM of NO and 30mM of zebularine for 7 days. (2)
In vitro differentiation to generate derivatives of the three primary germ layers: EBs
were generated using the hanging drop method during 3 days in the absence of
LIF, and then plated and incubated for 24 h in a 10-cm plastic dish in DMEM
medium without LIF to adhere, control cultures were left untreated and
experimental cultures were treated with 30 mM of zebularine for 3, 5 and 7 days;
in parallel cells cultured in monolayer without LIF and without generating EBs,
( LIF) were used as negative control. (3) Effect of zebularine on mESC
differentiation: EBs were generated as in experimental point 2 and the cells were
treated with 30mM of zebularine for 7 days (see Figure 2a).
The human ESC cell line (HS-181) was derived in the Fertility Unit of Karolinska
University Hospital, Huddinge at the Karolinska Institute after approval of a project
entitled ‘Derivation and early differentiation and characterization of hESC lines’ by
the Karolinska Institute Research Ethics Board South, Drno 454/02. This line was
derived from an embryo that could not be used for the infertility treatment of a
couple. Both partners of the couple signed a consent form for donation of the
embryo for derivation of a possible permanent stem cell line to be used in stem cell
research. The HS-181 line is included in the EU hESC registry (http://
www.hescreg.eu/) and cultured as described by Hovatta et al.36 To promote
differentiation, cells were cultured on Matrigel, bFGF was withdrawn from the
medium and cells were subjected to EB formation and 30 mM zebularine treatment
for 7 days, as described for mESCs.
Analysis of apoptosis. Apoptosis was evaluated using an Annexin-V-FITC
apoptosis detection kit II (BD Pharmingen, San Diego, CA, USA). Briefly, the cells
were divided into Control group, zebularine-treated group and Azad-C-treated group.
In each time point (3, 5 and 7 days), cells were trypsinized to prepare a single-cell
suspension (detached cells) and centrifuged at 1800 r/min for 6min at 4 1C. Cell
pellets were washed two times with cold PBS and then stained with Annexin-V-FITC
and propidium iodide (PI), following the manufacturer’s instructions. For each
sample, FITC-Annexin-V and PI staining were analyzed using Flow Cytometry (BD
FACSCalibur cytometry System, San Jose, CA, USA). The data were analyzed
using the CellQuest software (BD, San Jose, CA, USA).
Control samples were normalized to 1. The SPSS statistical package (v. 13.0, SPSS
Inc., Chicago, IL, USA) was used for statistical analysis. Data were analyzed for
statistical significance using one-way ANOVA and Tukey’s B test: an analysis of
variance type I (ANOVA I) was used to determine the statistical significance differences
between treatments. Once confirmed, Tukey’s B discriminatory analysis was performed
to determine the existence of significance differences between the groups.
Flow cytometry. Cardiac proteins expression was analyzed by flow
cytometry. Briefly, EBs were trypsinized and fixed with 4% paraformaldehyde.
The cells were treated with blocking solution (PBS containing 3% BSA, 0.1%
Triton X-100), and incubated for 1 h at 4 1C with primary anti-Gata4, anti-Actc, anti-
Flk1, anti-Myh7, anti-sarcomeric Actc, anti-Anf and anti-Desmin. After washing, the
cells were incubated for 30min with secondary antibodies. Unlabeled cells and cells
labeled with secondary antibody were used as controls. The data were analyzed
using the CellQuest software to calculate the percentage of positive cells.
RT-PCR analysis. Total RNA was extracted from control and treated cells
using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s instructions. RNA concentration was quantified using a NanoDrop
spectrophotometer, and 1 mg of total RNA was reverse transcribed using MMLV
retrotranscriptase (Promega, Madison, WI, USA) and random hexamers.
cDNA was amplified using 0.05 U/ml of Eco-Taq polymerase (Ecogen, Barcelona,
Spain) and 400 nM of specific primers. In all, 26 amplification cycles were used.
Quantitative real-time PCR was performed using SYBR-Green and detected using
an ABI Prism 7500 system (Applied Biosystems, Foster City, CA, USA). Primer
information is described in Supplementary Table 1.
Western blotting assay. Cells were lysed in RIPA buffer (Sigma-Aldrich, St
Louis, MO, USA) complete with protease inhibitors (Roche Diagnostics GmbH,
Mannheim, Germany). Protein concentration was quantified by Bradford colorimetric
assay (Sigma-Aldrich), and 20mg of proteins were separated using SDS-PAGE,
transferred to PDVF membrane and probed with anti-b-actin (Sigma-Aldrich; A5441),
anti-Actc (Santa Cruz Biotechnology, Dallas, TX, USA; SC15335), anti-Gata4 (Abcam,
Cambridge, UK; AB4132), anti-Myh7 (Santa Cruz Biotechnology; SC12117), anti-Anf
(Abcam; AB5490), anti-cTnT (Abcam; AB10214), anti-Desmin (Sigma-Aldrich; D8281),
anti-Flk1 (Millipore, Billerica, MA, USA; 07-716), anti-sarcomeric Actc (Sigma-Aldrich;
A7811), anti-acetyl histone H4 (Upstate, Lake Placid, NY, USA; 06-598), anti-
monomethyl Lys9 H3 (Upstate; 07-450) and anti-trimethyl Lys4 H3 (Upstate; 07-473).
Immunofluorescence staining. Cells were fixed and permeabilized with
methanol, incubated at  20 1C for 20min and blocked with donkey serum in PBS
(pH 7.4), and then labeled with appropriate primary antibodies (1:1000). The
primary antibodies used were mostly the same as those used for western blotting,
and the secondary antibodies used were Alexa Fluor 488 goat anti-rabbit
(Invitrogen; A11034), Alexa Fluor 488 goat anti-mouse (Invitrogen; A11029) and
Alexa Fluor 568 donkey anti-goat (Invitrogen; A11057). Digital images were
obtained using a Leica SP5 confocal microscope (Leica, Mannheim, Germany) or
an Olympus IX71 inverted microscope (Olympus, Tokyo, Japan).
Proteome profile array. Protein expression profiles were assayed using the
specific human pluripotent Stem Cell array kit ‘Proteome Profiler Array’ (R&D
Systems Europe, Abingdon, UK; ARY010) following the manufacturer’s
instructions. This array allowed us to detect simultaneously 15 different stem
cell markers related to pluripotency and differentiation processes. The
densitometry analysis of the resulting spots was carried out using the ImageJ
1.41 software (Wayne Rasband, NIH, Bethesda, MD, USA).
Chronotropic drugs treatment. Beating areas of cell culture treated with
zebularine were subjected to 2 mM isoproterenol, and the frequency of beating
was counted 1 and 2min after treatment. The medium was changed and 50mM
diltiazem was added to the cultures, and contractions were counted until they
stopped. Movies were captured on Olympus IX71 inverted microscope using
Olympus DP70 digital camera system (Olympus) and the Olympus DP Controller
software (Olympus).
Bisulfite modification and MSP. Genomic DNA was extracted by
phenol–chloroform extraction and purified using the Wizard DNA Clean-up system
(Promega). Bisulfite modification was performed using the EZ-DNA Methylation-
gold kit (Zymo Research Corp., Irvine, CA, USA) following the manufacturer’s
instructions. Specific primers (Supplementary Table 1) were designed using
Methyl Primer Express Software (Applied Biosystems), and MSP was performed
as follows: 95 1C for 3 min, 40 cycles of 95 1C for 30 s, 55 1C for 1 min, 72 1C for
1min and 72 1C for 7 min. Samples were loaded on a 2% agarose gel.
Bisulfite sequencing. DNA was isolated using DNeasy kit (Qiagen, Hilden,
Germany) from EBs (Control, Zebularine and Azad-C) grown for 7 days to allow
differentiation. In all, 1 mg of DNA was then bisulphite converted using the Cells-to-
CpGM Bisulfite Conversion kit (Applied Biosystems) according to the manufac-
turer’s recommendation. Methyl Primer Express Software (Applied Biosystems) was
Mesodermal differentiation by zebularine
A Horrillo et al
12
Cell Death and Disease
used to design primers for CpG islands flanking the same sequence region used for
MSP (Supplementary Table 1). Bisulfite-modified DNA was amplified using a hot
start Taq polymerase (MyTaq HS Red DNA Polymerase; Bioline Reagents Ltd.,
London, UK), starting with denaturation at 95 1C for 5min, and then 35 cycles of
denaturation at 95 1C for 30 s, annealing at optimal Tm for 15 s, extension at 72 1C
for 15 s, followed by an extra extension at 72 1C for 10min. Amplicons were purified
using the QIAquick PCR Purification kit (Qiagen) and were cloned in pGEM-T vector
at a 3:1 insert:vector molar ratio. DH5a-competent cells (Invitrogen) were
transformed by heat shock and grown overnight on LB-agar plates containing
ampicillin, X-gal and IPTG. CpG primers described above was used to amplify
bisulfite-modified DNA directly from 4 to 10 white colonies; amplicons were then
purified enzymatically with ExoSAP-IT (USB, Cleveland, OH, USA) and 50 ng of
PCR product were bidirectionally sequenced using the BigDye Terminator v.3.1
Cycle Sequencing kit (Applied Biosystems). Fragments were separated on an
ABI3730xl DNA Analyzer (Applied Biosystems) and analyzed with Variant Reporter
Software v.1.0 (Applied Biosystems). BiQ Analyzer software (Max-Planck-Institut,
Saarbru¨ken, Germany) was used to analyze methylation patterns and generate
diagrams. In all, 1mg of DNA from Control EBs was methylated by MSssI CpG
methyltransferase using the recommended protocol (New England Biolabs, Ipswich,
MA, USA) and used in parallel with samples as control for bisulfite conversion and
sequencing efficiency and accuracy.
Epigenetic enzyme activity analysis. The epigenetic enzyme activity
measurements and calculations were performed according to the manufacturer’s
protocols and formulas. DNMTs activity (Catalog no.: P-3001), HMT activity H3K4
(Catalog no.: P-3002), HMT activity H3K9 (Catalog no.: P-3003) and demethylase
activity (Catalog no.: P-3019) were measured using 10 mg of nuclear protein
extracts in the EpiQuik Kits (Epigentek, Farmingdale, NY, USA). HDAC activity
was analyzed using the HDAC Colorimetric Assay Kit (BioVision, Milpitas, CA,
USA), and the colorimetric intensity was measured using a Varioskan Flash
microplate reader (Thermo Electron, Vantaa, Finland). Nuclear proteins were
isolated using the Subcellular Proteome Extraction Kit (Calbiochem, San Diego,
USA), and 5 mg of extracts were used for this assay.
Microarray analysis. Total RNA was isolated using the RNeasy Mini Kit
(Qiagen), and 1mg was used to obtain the gene expression profile of each sample.
The signals were quantified using spectrophotometry and verified using a
microfluidics-based platform (Genomic core facility of CABIMER). All samples
showed the characteristics of high-quality RNA and were subjected to subsequent
analysis. cRNA was hybridized on an Affymetrix GeneChip Mouse Genome 430 2.0
Array (Affymetrix, Santa Clara, CA, USA). The data presented in this publication have
been deposited in NCBI’s GEO37 and are accessible through GEO Series accession
number GSE29072 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29072).
In addition, data were subjected to Gene Ontology analysis and IPA software to
determine the possible biological functions and pathways.
2D-DIGE proteomic analysis. Proteins were extracted with 30mM Tris,
7 M urea, 2 M thiourea and 4% (w/v) CHAPS, pH 8.0. Cells were then sonicated in
a Bioruptor and centrifuged at 12 000 r.p.m. at 4 1C for 10min. The supernatant
was collected, 1 ml of TCEP was added and samples were incubated for 30min in
the dark at 37 1C. Next, Cy3 or Cy5 dye was added (2ml) and the staining reaction
was stopped using 7M urea, 2 M thiourea, 4% (w/v) CHAPS, 2% (v/v) pharmalyte
and 130mM DTT. Proteins were quantified using the Bradford colorimetric assay
(Sigma-Aldrich), and 1D electrophoresis was performed with Inmobiline Drystrip
pH 3-11 NL, 18-cm strips (GE Healthcare, Buckinghamshire, UK). In all, 5mg of
protein were used per strip. The strips were focused in an IPGphor system for
22 h. 2D-PAGE was performed with 10% duracryl acrylamide gels (Genomics
Solutions, Ann Arbor, MI, USA), and electrophoresis was performed using an
Ettan Dalt VI system (Amersham, Buckinghamshire, UK) according to the following
protocol: 2.5W per gel for 30min, followed by a second step of 12.5W per gel for
5 h. Fluorescence was visualized using a Typhoon Trio (Amersham).
Statistical analysis. Values are presented as mean±S.D., unless otherwise
indicated, statistical significance was calculated using an unpaired Student’s t-test
and Po0.05 was considered significantly different.
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